Outlook for 2018

The company will launch a new Acetium product for smoking cessation in 2018. Biohit also has ongoing product registrations with distributors and licensors in several market areas, affecting turnover.

Many registrations are expected to be completed in 2018.

China’s business continues to be an important focus area in Biohit’s business in 2018. In addition to ongoing GastroPanel screening research, Biohit’s Chinese partner Biohit HealthCare (Hefei) Co. Ltd has begun the commercial manufacture and sale of the GastroPanel product in raw materials supplied by China Biohit. At the same time, sales of GastroPanel kits made in Finland are expected to continue to grow in the Chinese market.

Net sales is estimated to grow during the year 2018. The company does not estimate when the comparable earnings turn profitable.